

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS	17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAPLUS
NEWS	18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS	19	JAN 25	Annual Reload of MEDLINE database
NEWS	20	FEB 16	STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS	21	FEB 16	Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS	22	FEB 16	New FASTA Display Formats Added to USGENE and PCTGEN
NEWS	23	FEB 16	INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS	24	FEB 16	INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:06:41 ON 15 MAR 2010

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 11:06:54 ON 15 MAR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2010 HIGHEST RN 1209528-92-6

DICTIONARY FILE UPDATES: 12 MAR 2010 HIGHEST RN 1209528-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10569482newestnow.str



```

chain nodes :
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 29 30 31 36 37
38 39 43 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 69
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
7-43 11-12 11-45 12-13 12-14 15-16 15-46 16-17 18-19 18-47 19-20 21-22
21-23 22-48 24-25 24-49 25-26 29-30 29-50 30-31 36-37 36-38 51-52 52-53
53-54 55-56 56-57 58-59 59-60
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
5-7 6-10 7-8 7-43 8-9 9-10 11-12 11-45 12-13 12-14 15-16 15-46 16-17
18-19 18-47 19-20 21-22 22-48 24-25 24-49 29-30 29-50 36-37 36-38 51-52
52-53 53-54 55-56 56-57 58-59 59-60
exact bonds :
21-23 25-26 30-31
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

```

```
G2:[*1],[*2]
```

```
G3:[*3],[*4],[*5]
```

```
G4:[*6],[*7],[*8],[*9],[*10],[*11]
```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:CLASS 17:CLASS 18:Atom
19:CLASS 20:CLASS 21:CLASS 22:Atom 23:CLASS 24:Atom 25:CLASS 26:CLASS
29:Atom 30:CLASS 31:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 43:CLASS
45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS
53:CLASS 54:Atom 55:CLASS 56:CLASS 57:Atom 58:CLASS 59:CLASS 60:Atom
69:CLASS 70:Atom

```

```
=> fil reg
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.49	0.71

FILE 'REGISTRY' ENTERED AT 11:07:03 ON 15 MAR 2010
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2010 HIGHEST RN 1209528-92-6
 DICTIONARY FILE UPDATES: 12 MAR 2010 HIGHEST RN 1209528-92-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10569482newestnow.str



chain nodes :
 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 29 30 31 36 37
 38 39 43 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 69
 ring nodes :
 1 2 3 4 5 6 7 8 9 10
 chain bonds :
 7-43 11-12 11-45 12-13 12-14 15-16 15-46 16-17 18-19 18-47 19-20 21-22
 21-23 22-48 24-25 24-49 25-26 29-30 29-50 30-31 36-37 36-38 51-52 52-53
 53-54 55-56 56-57 58-59 59-60
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
 exact/norm bonds :
 5-7 6-10 7-8 7-43 8-9 9-10 11-12 11-45 12-13 12-14 15-16 15-46 16-17
 18-19 18-47 19-20 21-22 22-48 24-25 24-49 29-30 29-50 36-37 36-38 51-52
 52-53 53-54 55-56 56-57 58-59 59-60

exact bonds :
21-23 25-26 30-31
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G2:[*1],[*2]

G3:[*3],[*4],[*5]

G4:[*6],[*7],[*8],[*9],[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:CLASS 17:CLASS 18:Atom
19:CLASS 20:CLASS 21:CLASS 22:Atom 23:CLASS 24:Atom 25:CLASS 26:CLASS
29:Atom 30:CLASS 31:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 43:CLASS
45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS 52:CLASS
53:CLASS 54:Atom 55:CLASS 56:CLASS 57:Atom 58:CLASS 59:CLASS 60:Atom
69:CLASS 70:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:07:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11064 TO ITERATE

18.1% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 214975 TO 227585
PROJECTED ANSWERS: 87 TO 575

L2 3 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 11:07:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 220266 TO ITERATE


100.0% PROCESSED 220266 ITERATIONS 214 ANSWERS
SEARCH TIME: 00.00.03

L3 214 SEA SSS FUL L1

=> d scan

L3 214 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 4H-1,4-Benzoxazine-4-butanoic acid,
2-(aminocarbonyl)-2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-
MF C31 H34 N2 O5

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

191.54

192.25

FILE 'CAPLUS' ENTERED AT 11:07:40 ON 15 MAR 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Mar 2010 VOL 152 ISS 12

FILE LAST UPDATED: 14 Mar 2010 (20100314/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 11:06:41 ON 15 MAR 2010)

FILE 'REGISTRY' ENTERED AT 11:06:54 ON 15 MAR 2010

FILE 'REGISTRY' ENTERED AT 11:07:03 ON 15 MAR 2010

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 214 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:07:40 ON 15 MAR 2010

=> s l3

L4 5 L3

=> d 1-5 ibib abs hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:773795 CAPLUS

DOCUMENT NUMBER: 149:104606

TITLE: Piperidine-nitro derivatives as nonpeptidic renin inhibitors, their pharmaceutical compositions and use in the treatment of diseases

INVENTOR(S): Almirante, Nicoletta; Biondi, Stefano; Ongini, Ennio

PATENT ASSIGNEE(S): Nicox S.A., Fr.

SOURCE: PCT Int. Appl., 218pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008074450	A2	20080626	WO 2007-EP11078	20071213
WO 2008074450	A3	20090108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2006-875816P P 20061220

OTHER SOURCE(S): MARPAT 149:104606

GI



II

AB Nonpeptidic renin inhibitors nitro derivs. of general formula I: having wider pharmacol. activity and enhanced tolerability. They can be employed for treating or preventing cardiovascular, renal and chronic liver diseases, inflammatory processes and metabolic syndrome. Compds. of formula I wherein A¹ is substituted (mono/bi)azacycle; j is 1, 2, and 3; X^a is (un)branched CO-C₁-20 alkylene, (un)branched CO₂-C₁-20 alkylene, CO-(CH₂)₀-20-aryl-(CH₂)₁-20, CO₂-(CH₂)₀-20-aryl-(CH₂)₁-20, etc.; and their pharmaceutically acceptable salts, and stereoisomers thereof, are claimed. Compound II may be prepared by a general procedure. The compds. of the invention may be used as nonpeptidic renin inhibitors.

IT 1034705-05-9P 1034705-06-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of piperazine-nitro derivs. of nonpeptidic renin inhibitors and their use in treating cardiovascular, renal, and liver diseases, inflammation, and metabolic syndrome)

RN 1034705-05-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 3-[[[3,4-dihydro-4-(3-methoxypropyl)-2H-1,4-benzoxazin-6-yl]oxy]methyl]-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, 4-[(nitrooxy)methyl]phenyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 1034705-06-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 3-[[[3,4-dihydro-4-(3-methoxypropyl)-2H-1,4-benzoxazin-6-yl]oxy]methyl]-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-, 3-[(nitrooxy)methyl]phenyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:793715 CAPLUS

DOCUMENT NUMBER: 147:189075

TITLE: 3,4,5-Substituted piperidines as β -secretase, cathepsin D, plasmepsin II and HIV protease inhibitors and their preparation and use in the treatment of diseases

INVENTOR(S): Herold, Peter; Mah, Robert; Stutz, Stefan; Tschinke, Vincenzo; Schumacher, Christoph; Stojanovic, Aleksandar; Jotterand, Nathalie; Behnke, Dirk

PATENT ASSIGNEE(S): Speedel Experimenta AG, Switz.

SOURCE: U.S. Pat. Appl. Publ., 108 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070167433	A1	20070719	US 2007-655108	20070119
EP 1816122	A2	20070808	EP 2007-100713	20070118
EP 1816122	A3	20070919		



R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

PRIORITY APPLN. INFO.: CH 2006-88 A 20060119

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 147:189075

GI



AB Use of compds. of the general formula I and pharmaceutically acceptable salt thereof, as β secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors. Compds. of formula I wherein R1 is (un)substituted heterocyclyl and (un)substituted aryl; R2 is Ph, naphthyl, acenaphthyl, pyridinyl, pyrimidinyl, etc.; R3 is H, OH, C1-8 alkoxy, and C1-8 alkenyloxy; R4 is (un)substituted C1-8 alkyl, (un)substituted C1-8 alkoxy-C1-8 alkyl, (mono/di)-C1-8 alkylamino-C1-8 alkyl, etc.; X is a bond, O, S, (un)substituted methylene, CHOH and derivs., etc.; W is O and S; Z is (un)substituted C1-8 alkylene, C2-8 alkenylene, O, N, S, etc.; n is 1 or n is 0 and 1 when X is OCO; m is 0 and 1; and their pharmaceutically acceptable salts, prodrugs, and stable non-radioactive isotopes thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their β -secretase, cathepsin D, plasmepsin II and HIV protease inhibitory activity.

IT 912347-18-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of trisubstituted piperidines as β -secretase, cathepsin D, plasmepsin II and HIV-protease inhibitors useful in the treatment of diseases)

RN 912347-18-3 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[2-[(3R,4S,5S)-4-[4-[(2-methoxyethoxy)methyl]phenyl]-1-[(4-methylphenyl)sulfonyl]-5-[(2R)-2-oxiranylmethoxy]-3-piperidinyl]ethyl]-4-(3-methoxypropyl)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1030984 CAPLUS

DOCUMENT NUMBER: 145:419157

TITLE: Preparation of 3,4,5-substituted piperidines as renin inhibitors

INVENTOR(S): Herold, Peter; Mah, Robert; Tschinke, Vincenzo; Jotterand, Nathalie; Behnke, Dirk; Stojanovic, Aleksandar; Stutz, Stefan; Quirmbach, Michael; Jelakovic, Stjepan

PATENT ASSIGNEE(S): Speedel Experimenta AG, Switz.

SOURCE: PCT Int. Appl., 128pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006103275	A1	20061005	WO 2006-EP61193	20060330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2601108	A1	20061005	CA 2006-2601108	20060330
EP 1863763	A1	20071212	EP 2006-743229	20060330
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008535825	T	20080904	JP 2008-503524	20060330
US 20090270380	A1	20091029	US 2007-887354	20070928
CN 101151247	A	20080326	CN 2006-80010622	20070929
IN 2007DN08234	A	20071123	IN 2007-DN8234	20071025
PRIORITY APPLN. INFO.:			CH 2005-593	A 20050331


CH 2006-86 A 20060119

WO 2006-EP61193 W 20060330

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:419157; MARPAT 145:419157

GI




AB The application relates to novel substituted piperidines of the general formula I (wherein R1 = (un)substituted aryl or heterocyclyl; R2' = C2-8alkenyloxy-C1-8alkyl, C1-8alkoxy-C1-8alkyl, etc.; R2'' = halogen; R4' = (un)substituted C1-8alkoxy, C1-8alkoxy-C1-8alkoxy, etc.; X = a bond, O or S; Z = C1-8alkylene, C2-8alkenylene, etc.; m = 0-2; and n = 0-1), to a process for the preparation thereof, and to the use of these compds. as medicines, especially as renin inhibitors. I can be used to prevent, delay the progression, or treat high blood pressure, heart failure, glaucoma, myocardial infarction, renal failure, restenoses or stroke in humans. For example, II was prepared in a 17 step synthesis starting from the reduction of Me 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate. In renin inhibition tests that measure reduction in angiotensin I formation in vitro, I showed inhibitory activity at minimal concns. of about 10⁻⁶ - 10⁻¹⁰ mol/l.

IT 912347-18-3P, 6-[2-[(3R,4S,5S)-4-[4-[2-Methoxyethoxymethyl]phenyl]-5-[(R)-1-[oxiranylmethyl]oxy]-1-(4-tolylsulfonyl)piperidin-3-yl]ethyl]-4-(3-methoxypropyl)-3,4-dihydro-2H-benzo[1,4]oxazine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3,4,5-substituted piperidines as renin inhibitors)

RN 912347-18-3 CAPLUS

CN 2H-1,4-Benzoxazine, 3,4-dihydro-6-[2-[(3R,4S,5S)-4-[4-[(2-methoxyethoxy)methyl]phenyl]-1-[(4-methylphenyl)sulfonyl]-5-[(2R)-2-oxiranylmethoxy]-3-piperidinyl]ethyl]-4-(3-methoxypropyl)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:219785 CAPLUS

DOCUMENT NUMBER: 142:298120

TITLE: Preparation of 3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid derivatives as cysLT2 receptor antagonists for treatment of respiratory diseases

INVENTOR(S): Takeuchi, Jun; Itadani, Satoshi; Nakayama, Yoshisuke; Tatsumi, Tadashi; Takahashi, Shinya; Fujita, Manabu

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 237 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021518	A1	20050310	WO 2004-JP12563	20040831
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004268865	A1	20050310	AU 2004-268865	20040831
CA 2537355	A1	20050310	CA 2004-2537355	20040831
EP 1661892	A1	20060531	EP 2004-772519	20040831
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1845911	A	20061011	CN 2004-80025056	20040831
BR 2004013968	A	20061031	BR 2004-13968	20040831
ZA 2006001423	A	20070425	ZA 2006-1423	20040831

RU 2371436	C2	20091027	RU 2006-110513	20040831
NZ 545666	A	20091127	NZ 2004-545666	20040831
MX 2006002152	A	20060522	MX 2006-2152	20060224
KR 2006119903	A	20061124	KR 2006-704215	20060228
IN 2006KN00756	A	20070323	IN 2006-KN756	20060329
NO 2006001513	A	20060601	NO 2006-1513	20060403
US 20060194797	A1	20060831	US 2006-569482	20060405
PRIORITY APPLN. INFO.:			JP 2003-309232	A 20030901
			JP 2003-369547	A 20031029
			WO 2004-JP12563	W 20040831

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 142:298120
 GI




AB The title benzoxazine derivs. I [wherein R1 and R2 = independently (un)substituted acid group; D and E = independently a bond or a spacer; R3 = a substituent; ring A = (un)substituted cyclyl; ring B = (un)substituted cyclyl; Y and Z = independently C or N] or N-oxides, salts, solvates, or prodrugs thereof are prepared as cysteinyl leukotriene receptor LT-2 (cysLT2) antagonists. For example, the compound II was prepared in a multi-step synthesis. I inhibited cysLT2 with IC50 of <10 μ M. I are useful for the treatment of respiratory diseases, such as bronchial asthma, chronic obstructive lung disease, pulmonary emphysema, chronic bronchitis, pneumonia, severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis, etc. (no data). Formulations containing I as an active ingredient were also described.

IT 847655-65-6P 847655-66-7P
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (drug candidate; preparation of benzoxazine derivs. as cysLT2 receptor antagonists for treatment of respiratory diseases)


RN 847655-65-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 847655-66-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-, (2R)- (CA
 INDEX NAME)


Absolute stereochemistry.




IT 847655-51-0P 847656-55-7P 847656-56-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of benzoxazine derivs. as cysLT2 receptor
 antagonists for treatment of respiratory diseases)
 RN 847655-51-0 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX
 NAME)



RN 847656-55-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-, 4-methyl
 ester (CA INDEX NAME)



RN 847656-56-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-
 [[(phenylsulfonyl)amino]carbonyl]-, methyl ester (CA INDEX NAME)



IT	847655-38-3P	847655-39-4P	847655-40-7P
	847655-41-8P	847655-42-9P	847655-43-0P
	847655-44-1P	847655-45-2P	847655-46-3P
	847655-47-4P	847655-48-5P	847655-49-6P
	847655-50-9P	847655-52-1P	847655-53-2P
	847655-54-3P	847655-56-5P	847655-57-6P
	847655-60-1P	847655-62-3P	847655-63-4P
	847655-64-5P	847655-67-8P	847655-68-9P
	847655-70-3P	847655-71-4P	847655-72-5P
	847655-74-7P	847655-75-8P	847655-76-9P
	847655-78-1P	847655-80-5P	847655-81-6P
	847655-82-7P	847655-83-8P	847655-84-9P
	847655-85-0P	847655-86-1P	847655-89-4P
	847655-90-7P	847655-91-8P	847655-92-9P
	847655-93-0P	847655-94-1P	847656-01-3P
	847656-02-4P	847656-04-6P	847656-05-7P
	847656-06-8P	847656-07-9P	847656-09-1P
	847656-10-4P	847656-11-5P	847656-12-6P
	847656-13-7P	847656-15-9P	847656-23-9P
	847656-24-0P	847656-25-1P	847656-26-2P
	847656-27-3P	847656-29-5P	847656-30-8P
	847656-31-9P	847656-32-0P	847656-33-1P
	847656-34-2P	847656-35-3P	847656-36-4P
	847656-37-5P	847656-38-6P	847656-39-7P
	847656-40-0P	847656-41-1P	847656-42-2P
	847656-43-3P	847656-44-4P	847656-45-5P
	847656-46-6P	847656-47-7P	847656-48-8P
	847656-49-9P	847656-50-2P	847656-51-3P
	847656-52-4P	847656-53-5P	847656-54-6P
	847656-57-9P	847656-58-0P	847656-59-1P
	847656-60-4P	847656-61-5P	847656-62-6P
	847656-63-7P	847656-64-8P	847656-65-9P
	847656-66-0P	847656-67-1P	847656-68-2P
	847656-69-3P	847656-70-6P	847656-71-7P
	847656-72-8P	847656-73-9P	847656-74-0P
	847656-75-1P	847656-76-2P	847656-77-3P
	847656-78-4P	847656-79-5P	847656-80-8P
	847656-81-9P	847656-82-0P	847656-83-1P
	847656-84-2P	847656-85-3P	847656-86-4P
	847656-88-6P	847656-90-0P	847656-91-1P


847656-92-2P	847656-93-3P	847656-94-4P
847656-95-5P	847656-96-6P	847656-97-7P
847656-98-8P	847656-99-9P	847657-00-5P
847657-01-6P	847657-02-7P	847657-03-8P
847657-04-9P	847657-05-0P	847657-06-1P
847657-07-2P	847657-08-3P	847657-09-4P
847657-10-7P	847657-11-8P	847657-12-9P
847657-13-0P	847657-14-1P	847657-15-2P
847657-16-3P	847657-17-4P	847657-18-5P
847657-19-6P	847657-20-9P	847657-21-0P
847657-22-1P	847657-23-2P	847657-24-3P
847657-25-4P	847657-26-5P	847657-27-6P
847657-28-7P	847657-29-8P	847657-30-1P
847657-32-3P	847657-33-4P	847657-34-5P
847657-35-6P	847657-36-7P	847657-37-8P
847657-38-9P	847657-39-0P	847657-40-3P
847657-41-4P	847657-42-5P	847657-43-6P
847657-44-7P	847657-45-8P	847657-46-9P
847657-51-6P	847657-54-9P	847657-96-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzoxazine derivs. as cysLT2 receptor antagonists for treatment of respiratory diseases)


RN 847655-38-3 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro- γ -oxo-8-[[4-(4-phenylbutoxy)benzoyl]amino]-
(CA INDEX NAME)




RN 847655-39-4 CAPLUS


CN 4H-1,4-Benzoxazine-4-pentanoic acid,
2-carboxy-2,3-dihydro- δ -oxo-8-[[4-(4-phenylbutoxy)benzoyl]amino]-
(CA INDEX NAME)



RN 847655-40-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-hexanoic acid,
 2-carboxy-2,3-dihydro-ε-oxo-8-[[4-(4-phenylbutoxy)benzoyl]amino]-
 (CA INDEX NAME)




RN 847655-41-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-γ-oxo-6-[[4-(4-phenylbutoxy)benzoyl]amino]-
 (CA INDEX NAME)




RN 847655-42-9 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro- γ -oxo-7-[[4-(4-phenylbutoxy)benzoyl]amino]-
(CA INDEX NAME)




RN 847655-43-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2,3-dihydro- γ -oxo-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-(2H-
tetrazol-5-yl)- (CA INDEX NAME)




RN 847655-44-1 CAPLUS


CN 4H-1,4-Benzoxazine-4-pentanoic acid,
2,3-dihydro- δ -oxo-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-(2H-
tetrazol-5-yl)- (CA INDEX NAME)




RN 847655-45-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-hexanoic acid,
 2,3-dihydro-ε-oxo-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-(2H-
 tetrazol-5-yl)- (CA INDEX NAME)




RN 847655-46-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-γ-oxo-6-[[4-(4-phenylbutoxy)benzoyl]amino]-2-(2H-
 tetrazol-5-yl)- (CA INDEX NAME)




RN 847655-47-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-γ-oxo-7-[[4-(4-phenylbutoxy)benzoyl]amino]-2-(2H-
 tetrazol-5-yl)- (CA INDEX NAME)




RN 847655-48-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-γ-oxo-8-[[4-(4-phenylbutoxy)phenyl]methoxy]-
 (CA INDEX NAME)




RN 847655-49-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenylbutoxy)phenyl]methoxy]- (CA INDEX
 NAME)




RN 847655-50-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-pentanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenylbutoxy)phenyl]methoxy]- (CA INDEX
 NAME)




RN 847655-52-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-propanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenylbutoxy)phenyl]methoxy]- (CA INDEX
 NAME)




RN 847655-53-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA
 INDEX NAME)




RN 847655-54-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(aminocarbonyl)-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA
 INDEX NAME)




RN 847655-56-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-(2H-tetrazol-5-yl)-
 (CA INDEX NAME)




RN 847655-57-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-hexanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX
 NAME)



RN 847655-60-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenoxybutyl)phenyl]methoxy]- (CA INDEX
 NAME)




RN 847655-62-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[[4-(4-phenylbutoxy)phenyl]methyl]amino]- (CA
 INDEX NAME)




RN 847655-63-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]- (CA
 INDEX NAME)


Double bond geometry as shown.




RN 847655-64-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[2-[4-(4-phenylbutoxy)phenyl]ethyl]- (CA INDEX
 NAME)



RN 847655-67-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[2-methyl-4-(4-phenylbutoxy)benzoyl]amino]- (CA
 INDEX NAME)




RN 847655-68-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[[2,6-dimethyl-4-(4-phenylbutoxy)benzoyl]amino]-2,3-dihydro-
 (CA INDEX NAME)



RN 847655-70-3 CAPLUS


CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1Z)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]- (CA
INDEX NAME)

Double bond geometry as shown.




RN 847655-71-4 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[2-(2,3-dihydro-1H-inden-2-yl)ethoxy]benzoyl]amino]-2,3-
dihydro- (CA INDEX NAME)




RN 847655-72-5 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-(phenylmethoxy)benzoyl]amino]- (CA INDEX
NAME)




RN 847655-74-7 CAPLUS


CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-(3-phenylpropoxy)benzoyl]amino]- (CA INDEX
NAME)




RN 847655-75-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[(5-phenylpentyl)oxy]benzoyl]amino]- (CA
 INDEX NAME)




RN 847655-76-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[(6-phenylhexyl)oxy]benzoyl]amino]- (CA INDEX
 NAME)



RN 847655-78-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[(7-phenylheptyl)oxy]benzoyl]amino]- (CA
 INDEX NAME)




RN 847655-80-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[2-(phenylmethoxy)benzoyl]amino]- (CA INDEX
 NAME)




RN 847655-81-6 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[3-(phenylmethoxy)benzoyl]amino]- (CA INDEX
NAME)




RN 847655-82-7 CAPLUS


CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-(2-phenylethoxy)benzoyl]amino]- (CA INDEX
NAME)



RN 847655-83-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[2-(3-phenylpropoxy)benzoyl]amino]- (CA INDEX
 NAME)




RN 847655-84-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[3-(3-phenylpropoxy)benzoyl]amino]- (CA INDEX
 NAME)




RN 847655-85-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[2-[(5-phenylpentyl)oxy]benzoyl]amino]- (CA
INDEX NAME)




RN 847655-86-1 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[2-[(6-phenylhexyl)oxy]benzoyl]amino]- (CA INDEX
NAME)




RN 847655-89-4 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[2-(2-phenylethoxy)benzoyl]amino]- (CA INDEX
NAME)




RN 847655-90-7 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[2-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX
NAME)




RN 847655-91-8 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[3-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX
NAME)




RN 847655-92-9 CAPLUS


CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[3-(2-phenylethoxy)benzoyl]amino]- (CA INDEX
NAME)



RN 847655-93-0 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[3-[(6-phenylhexyl)oxy]benzoyl]amino]- (CA INDEX
 NAME)




RN 847655-94-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[3-[(5-phenylpentyl)oxy]benzoyl]amino]- (CA
 INDEX NAME)



RN 847656-01-3 CAPLUS


CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-(2-phenoxyethoxy)benzoyl]amino]- (CA INDEX
NAME)




RN 847656-02-4 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[(5-methyl-3-isoxazolyl)methoxy]benzoyl]amino]-
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 847656-04-6 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
8-[[4-(2-benzothiazolylmethoxy)benzoyl]amino]-2-carboxy-2,3-dihydro- (CA
INDEX NAME)




RN 847656-05-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[4-[(4'-methoxy[1,1'-biphenyl]-4-yl)oxy]butoxy]benzoyl]amino]- (CA INDEX NAME)

PAGE 1-A






RN 847656-06-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(3-phenoxypropoxy)benzoyl]amino]- (CA INDEX
 NAME)




PhO-(CH₂)₃-O


RN 847656-07-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(4-phenoxybutoxy)benzoyl]amino]- (CA INDEX
 NAME)




RN 847656-09-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[2-(2-naphthalenyl)ethoxy]benzoyl]amino]- (CA
 INDEX NAME)




RN 847656-10-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[2-(1-naphthalenyl)ethoxy]benzoyl]amino]- (CA
 INDEX NAME)




RN 847656-11-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[[4-[(2,3-dihydro-1H-inden-2-yl)methoxy]benzoyl]amino]-2,3-
 dihydro- (CA INDEX NAME)




RN 847656-12-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(2-naphthalenylmethoxy)benzoyl]amino]- (CA
 INDEX NAME)



RN 847656-13-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-(1-naphthalenylmethoxy)benzoyl]amino]- (CA
 INDEX NAME)




RN 847656-15-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[[4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]benzoyl]amino]-2,3-
 dihydro- (CA INDEX NAME)




RN 847656-23-9 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-7-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX
NAME)





RN 847656-24-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-7-[[3-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX
NAME)




RN 847656-25-1 CAPLUS


CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[4-(4-fluorophenyl)butoxy]benzoyl]amino]-2,3-dihydro- (CA
INDEX NAME)



RN 847656-26-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-6-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX
 NAME)




RN 847656-27-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-6-[[3-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX
 NAME)




RN 847656-29-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[4-(4-methylphenyl)butoxy]benzoyl]amino]- (CA
 INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-30-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[4-(4-methoxyphenyl)butoxy]benzoyl]amino]-
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-31-9 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[4-(2-methylphenoxy)butoxy]benzoyl]amino]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-32-0 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[4-(3-methylphenoxy)butoxy]benzoyl]amino]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-33-1 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[4-(4-methylphenoxy)butoxy]benzoyl]amino]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-34-2 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[4-(2-fluorophenoxy)butoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-35-3 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[4-(2-methoxyphenoxy)butoxy]benzoyl]amino]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-36-4 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[4-(2-chlorophenoxy)butoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-37-5 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[4-[2-(trifluoromethyl)phenoxy]butoxy]benzoyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-38-6 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(2-fluorophenoxy)propoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-39-7 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(3-fluorophenoxy)propoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-40-0 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(3-chlorophenoxy)propoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-41-1 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(2-chlorophenoxy)propoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-42-2 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[3-[3-(trifluoromethyl)phenoxy]propoxy]benzoyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-43-3 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[3-[2-
(trifluoromethyl)phenoxy]propoxy]benzoyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-44-4 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[3-(2-methylphenoxy)propoxy]benzoyl]amino]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-45-5 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(4-fluorophenoxy)propoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-46-6 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(2-chloro-4-fluorophenoxy)propoxy]benzoyl]amino]-2,3-
dihydro- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-47-7 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(4-chlorophenoxy)propoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-48-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[[4-[3-(4-methylphenoxy)propoxy]benzoyl]amino]-
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-49-9 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[[4-[3-(3-methylphenoxy)propoxy]benzoyl]amino]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-50-2 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[4-(3-chlorophenoxy)butoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-51-3 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(2,6-dichlorophenoxy)propoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-52-4 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[3-(2,6-dimethylphenoxy)propoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-53-5 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[4-(2,6-difluorophenoxy)butoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847656-54-6 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[[4-[4-(2,6-dichlorophenoxy)butoxy]benzoyl]amino]-2,3-dihydro-
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 847656-57-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-
 [[(phenylsulfonyl)amino]carbonyl]- (CA INDEX NAME)




RN 847656-58-0 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-59-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-60-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[(2-chlorophenyl)sulfonyl]amino]carbonyl]-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-61-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[(3-chlorophenyl)sulfonyl]amino]carbonyl]-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-62-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-63-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[[[(methylsulfonyl)amino]carbonyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]]- (CA INDEX NAME)




RN 847656-64-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-
 [[[(phenylmethyl)sulfonyl]amino]carbonyl]]- (CA INDEX NAME)




RN 847656-65-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-
 [[[(trifluoromethyl)sulfonyl]amino]carbonyl]- (CA INDEX NAME)




RN 847656-66-0 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-8-[[4-(4-
 phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-67-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[[[(6-methyl-2-pyridinyl)sulfonyl]amino]carbonyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-68-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-[[(2-thienylsulfonyl)amino]carbonyl]- (CA INDEX NAME)




RN 847656-69-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[[[(4-methyl-3-pyridinyl)sulfonyl]amino]carbonyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)



RN 847656-70-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[[[(3-methylphenyl)sulfonyl]amino]carbonyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-71-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[(ethylsulfonyl)amino]carbonyl]-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]]- (CA INDEX NAME)




RN 847656-72-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[(1E)-2-phenylethenyl]sulfonyl]amino]carbonyl]- (CA INDEX NAME)


Double bond geometry as shown.




RN 847656-73-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[(1,2-dimethyl-1H-imidazol-4-yl)sulfonyl]amino]carbonyl]-2,3-dihydro-8-
 [[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-74-0 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]carbonyl]-2,3-dihydro-8-[[4-
 (4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-75-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]carbonyl]- (CA INDEX NAME)



RN 847656-76-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]carbonyl]-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-77-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[[[(1,1-dimethylethyl)sulfonyl]amino]carbonyl]-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-78-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-2-[[phenylsulfonyl]amino]carbonyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 847656-79-5 CAPLUS
 CN 2H-1,4-Benzoxazine-2-carboxylic acid,
 3,4-dihydro-4-[4-[(methanesulfonyl)amino]-4-oxobutyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




RN 847656-80-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-7-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 847656-81-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[(5-phenylpentyl)oxy]phenyl]ethenyl]-
 (CA INDEX NAME)

Double bond geometry as shown.



RN 847656-82-0 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-(4-phenoxybutoxy)phenyl]ethenyl]- (CA
 INDEX NAME)


Double bond geometry as shown.



RN 847656-83-1 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-(3-phenylpropoxy)phenyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.



RN 847656-84-2 CAPLUS


CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[(2,3-dihydro-1H-inden-2-yl)methoxy]phenyl]ethenyl]-
2,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 847656-85-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[(1E)-2-[4-[(7-chloro-2-quinolinyl)methoxy]phenyl]ethenyl]-2,3-
 dihydro- (CA INDEX NAME)


Double bond geometry as shown.




RN 847656-86-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[(1E)-2-[4-[[3-[(7-chloro-2-
 quinolinyl)methoxy]phenyl]methoxy]phenyl]ethenyl]-2,3-dihydro- (CA INDEX
 NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 847656-88-6 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]phenyl]ethenyl]-2,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 847656-90-0 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[(5-phenoxy)pentyl]oxy]phenyl]ethenyl]-
 (CA INDEX NAME)


Double bond geometry as shown.



RN 847656-91-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[4-(3-methoxyphenoxy)butoxy]phenyl]ethenyl]- (CA INDEX NAME)



Double bond geometry as shown.





RN 847656-92-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[4-(4-
 methoxyphenoxy)butoxy]phenyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.




RN 847656-93-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[4-(3-
 methylphenoxy)butoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847656-94-4 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[4-(3-fluorophenoxy)butoxy]phenyl]ethenyl]-2,3-
dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847656-95-5 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[4-(2-
methylphenoxy)butoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847656-96-6 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[4-(4-fluorophenoxy)butoxy]phenyl]ethenyl]-2,3-
dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847656-97-7 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[4-(4-
methylphenoxy)butoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847656-98-8 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[4-(2-
methoxyphenoxy)butoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A





PAGE 2-A



RN 847656-99-9 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[4-(2-fluorophenoxy)butoxy]phenyl]ethenyl]-2,3-
dihydro- (CA INDEX NAME)


Double bond geometry as shown.




RN	847657-00-5	CAPLUS	
CN	4H-1,4-Benzoxazine-4-butanoic acid, 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[4-[2-(methylthio)phenoxy]butoxy]phenyl]ethenyl]- (CA INDEX NAME)		

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-01-6 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[3-(4-chlorophenyl)propoxy]phenyl]ethenyl]-2,3-
dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-02-7 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[3-(4-
methoxyphenyl)propoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-03-8 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[3-(3-
methylphenoxy)propoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-04-9 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[3-(3-fluorophenoxy)propoxy]phenyl]ethenyl]-2,3-
dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-05-0 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[3-(3-
methoxyphenoxy)propoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A





PAGE 2-A



RN 847657-06-1 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[3-(4-
methylphenoxy)propoxy]phenyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.




RN 847657-07-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[3-(2-
 methylphenoxy)propoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-08-3 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[3-(4-fluorophenoxy)propoxy]phenyl]ethenyl]-2,3-
dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-09-4 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-[3-(4-
methoxyphenoxy)propoxy]phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-10-7 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[3-(3-chlorophenoxy)propoxy]phenyl]ethenyl]-2,3-
dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-11-8 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[2-(2,3-dihydro-1H-inden-2-yl)ethoxy]phenyl]ethenyl]-2,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 847657-12-9 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[(1E)-2-[4-(3-phenoxypropoxy)phenyl]ethenyl]- (CA
INDEX NAME)


Double bond geometry as shown.




RN 847657-13-0 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[(1E)-2-[4-[3-(2-chlorophenoxy)propoxy]phenyl]ethenyl]-2,3-
 dihydro- (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A







RN 847657-14-1 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[(1E)-2-[4-[4-(2-chlorophenoxy)butoxy]phenyl]ethenyl]-2,3-
 dihydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 847657-15-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[(1E)-2-[4-[4-(3-chlorophenoxy)butoxy]phenyl]ethenyl]-2,3-
 dihydro- (CA INDEX NAME)


Double bond geometry as shown.




RN 847657-16-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[(1E)-2-[4-[4-(2,6-dichlorophenoxy)butoxy]phenyl]ethenyl]-2,3-
 dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 847657-17-4 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[4-(2,6-dimethylphenoxy)butoxy]phenyl]ethenyl]-2,3-
dihydro- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A





PAGE 2-A




RN 847657-18-5 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[(1E)-2-[4-[4-(2-chloro-6-methylphenoxy)butoxy]phenyl]ethenyl]-
2,3-dihydro- (CA INDEX NAME)

Double bond geometry as shown.




RN 847657-19-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-7-[(1E)-2-[4-(2-phenylethoxy)phenyl]ethenyl]- (CA
 INDEX NAME)

Double bond geometry as shown.




RN 847657-20-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[2-[4-(4-phenoxybutoxy)phenyl]ethyl]- (CA INDEX)

NAME)




RN 847657-21-0 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[2-[4-(3-phenylpropoxy)phenyl]ethyl]- (CA INDEX
NAME)




RN 847657-22-1 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[2-[4-[(2,3-dihydro-1H-inden-2-yl)methoxy]phenyl]ethyl]-2,3-
dihydro- (CA INDEX NAME)




RN 847657-23-2 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[2-[4-[3-(2,3-dihydro-1H-inden-2-yl)propoxy]phenyl]ethyl]-2,3-
dihydro- (CA INDEX NAME)




RN 847657-24-3 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[2-[4-[(5-phenoxy)pentyl]oxy]phenyl]ethyl]- (CA
INDEX NAME)




RN 847657-25-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[2-[4-[4-(3-methoxyphenoxy)butoxy]phenyl]ethyl]-
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-26-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[2-[4-[4-(4-methoxyphenoxy)butoxy]phenyl]ethyl]-
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-27-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[2-[4-[4-(3-methylphenoxy)butoxy]phenyl]ethyl]-
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-28-7 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[2-[4-[4-(3-fluorophenoxy)butoxy]phenyl]ethyl]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-29-8 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[2-[4-[4-(2-methylphenoxy)butoxy]phenyl]ethyl]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-30-1 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[2-[4-[4-(4-methylphenoxy)butoxy]phenyl]ethyl]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-32-3 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[2-[4-[4-(2-methoxyphenoxy)butoxy]phenyl]ethyl]-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-33-4 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-8-[2-[4-[4-(2-fluorophenoxy)butoxy]phenyl]ethyl]-2,3-dihydro-
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-34-5 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[2-[4-[3-(4-methylphenoxy)propoxy]phenyl]ethyl]-
(CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 847657-35-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro-8-[2-[4-[3-(2-methylphenoxy)propoxy]phenyl]ethyl]-
 (CA INDEX NAME)




RN	847657-36-7	CAPLUS
CN	4H-1,4-Benzoxazine-4-butanoic acid, 2-carboxy-2,3-dihydro-8-[2-[4-[3-(3-methylphenoxy)propoxy]phenyl]ethyl]- (CA INDEX NAME)	

PAGE 1-A




PAGE 2-A




RN 847657-37-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-8-[2-[4-[3-(3-fluorophenoxy)propoxy]phenyl]ethyl]-2,3-dihydro-
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 847657-38-9 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-carboxy-2,3-dihydro-8-[2-[4-[3-(3-methoxyphenoxy)propoxy]phenyl]ethyl]-
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 847657-39-0 CAPLUS
CN 4H-1,4-Benzoxazine-4-butanoic acid,
2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-2-(2H-tetrazol-5-yl)-,
ethyl ester (CA INDEX NAME)




RN 847657-40-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[2-[4-(4-phenylbutoxy)phenyl]ethyl]-2-(2H-tetrazol-5-yl)-
 (CA INDEX NAME)




RN 847657-41-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-2-(2H-tetrazol-5-yl)-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.




RN 847657-42-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-2-(2H-tetrazol-5-yl)- (CA INDEX NAME)

Double bond geometry as shown.




RN 847657-43-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(aminocarbonyl)-2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 847657-44-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)



RN 847657-45-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]- (CA INDEX NAME)


Double bond geometry as shown.



RN 847657-46-9 CAPLUS


CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 847657-51-6 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
2-(ethoxycarbonyl)-2,3-dihydro-8-[2-[4-(4-phenylbutoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 847657-54-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-carboxy-2,3-dihydro- γ -oxo-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 847657-96-9 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[(hydroxyamino)iminomethyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]- (CA INDEX NAME)




IT 847657-59-4P 847657-62-9P 847657-68-5P
 847657-69-6P 847657-74-3P 847657-76-5P
 847657-81-2P 847657-82-3P 847657-83-4P
 847657-84-5P 847657-85-6P 847657-86-7P
 847657-87-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzoxazine derivs. as cysLT₂ receptor antagonists for treatment of respiratory diseases)


RN 847657-59-4 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-γ-oxo-8-[[4-(4-phenylbutoxy)benzoyl]amino]-, methyl ester (CA INDEX NAME)




RN 847657-62-9 CAPLUS

CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-cyano-2,3-dihydro-γ-oxo-8-[[4-(4-phenylbutoxy)benzoyl]amino]-, methyl ester (CA INDEX NAME)




Ph-(CH₂)₄-O

RN 847657-68-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-γ-oxo-8-[[4-(4-phenylbutoxy)phenyl]methoxy]-, methyl ester (CA INDEX NAME)




Ph-(CH₂)₄-O


RN 847657-69-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-8-[[4-(4-phenylbutoxy)phenyl]methoxy]-, methyl ester (CA INDEX NAME)



RN 847657-74-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-,
 methyl ester (CA INDEX NAME)




RN 847657-76-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-8-[[[4-(4-phenylbutoxy)phenyl]methyl]amino]-,
 methyl ester (CA INDEX NAME)




RN 847657-81-2 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-8-[(1E)-2-[4-(4-
 phenylbutoxy)phenyl]ethenyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 847657-82-3 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-8-[(1E)-2-[4-(4-
 phenylbutoxy)phenyl]ethenyl]-, ethyl ester (CA INDEX NAME)


Double bond geometry as shown.




RN 847657-83-4 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(ethoxycarbonyl)-2,3-dihydro-8-[2-[4-(4-phenylbutoxy)phenyl]ethyl]-,
 ethyl ester (CA INDEX NAME)




RN 847657-84-5 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2,3-dihydro-2-[(hydroxyamino)iminomethyl]-8-[[4-(4-phenylbutoxy)benzoyl]amino]-,
 ethyl ester (CA INDEX NAME)



RN 847657-85-6 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(2,5-dihydro-5-oxo-1,2,4-thiadiazol-3-yl)-2,3-dihydro-8-[[4-(4-phenylbutoxy)benzoyl]amino]-, ethyl ester (CA INDEX NAME)




RN 847657-86-7 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-[(hydroxyamino)iminomethyl]-8-[2-[4-(4-phenylbutoxy)phenyl]ethenyl]-, ethyl ester (CA INDEX NAME)



RN 847657-87-8 CAPLUS
 CN 4H-1,4-Benzoxazine-4-butanoic acid,
 2-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-2,3-dihydro-8-[(1E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:424239 CAPLUS
 DOCUMENT NUMBER: 129:81735
 ORIGINAL REFERENCE NO.: 129:16877a,16880a

TITLE: Preparation of benzothiadiazolyloxobutenoates and analogs as endothelin receptor antagonists

INVENTOR(S): Dorsch, Dieter; Osswald, Mathias; Mederski, Werner; Wilm, Claudia; Schmitges, Claus Jochen; Christadler, Maria; Anzali, Soheila

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany; Dorsch, Dieter; Osswald, Mathias; Mederski, Werner; Wilm, Claudia; Schmitges, Claus Jochen; Christadler, Maria; Anzali, Soheila

SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827077	A1	19980625	WO 1997-EP7045	19971215
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19653037	A1	19980625	DE 1996-19653037	19961219
AU 9856635	A	19980715	AU 1998-56635	19971215
IN 1997CA02400	A	20050311	IN 1997-CA2400	19971218
PRIORITY APPLN. INFO.:			DE 1996-19653037	A 19961219
			WO 1997-EP7045	W 19971215
OTHER SOURCE(S):		MARPAT 129:81735		
GI				




AB Title compds. [tautomeric I; R = C(CO₂H):C(COR₃)(CH₂)_nR₂, COC[(CH₂)_nR₂]:CR₄CO₂H, (CH₂)_nC(COR₃):CR₄CO₂H; R₁ = H, halo, alkyl, alkoxy, etc.; R₂-R₄ = (un)substituted Ph, etc.; R₂ may addnl. = (cyclo)alkyl, etc.] were prepared as endothelin receptor antagonists (no data). Thus, 3,4-(H₂N)₂C₆H₃CH₂CO₂Et was cyclocondensed with PhN:SO and the product alkylated by 4-(MeO)C₆H₄COCH₂Br to give, in 2 addnl. steps, title compound II.

IT 1139049-41-4
RL: PRPH (Prophetic)
(Preparation of benzothiadiazolyloxobutenoates and analogs as endothelin receptor antagonists)

RN 1139049-41-4 CAPLUS

CN 2,1,3-Benzothiadiazole-5-acetic acid,

α -[1-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-6-yl)methyl]-2-oxo-2-[4-(phenylmethoxy)phenyl]ethylidene]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stnguide
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
29.55	221.80

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.25	-4.25

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 11:08:22 ON 15 MAR 2010
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Mar 12, 2010 (20100312/UP).

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
 LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.98	222.78

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-4.25

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:16:28 ON 15 MAR 2010